Marshall Financial Group LLC lowered its position in Eli Lilly and Company (NYSE:LLY – Free Report) by 2.3% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 4,232 shares of the company’s stock after selling 100 shares during the period. Eli Lilly and Company makes up approximately 1.1% of Marshall Financial Group LLC’s investment portfolio, making the stock its 19th largest holding. Marshall Financial Group LLC’s holdings in Eli Lilly and Company were worth $3,832,000 at the end of the most recent quarter.
A number of other institutional investors have also recently modified their holdings of the business. Raymond James & Associates lifted its stake in Eli Lilly and Company by 9.5% in the 2nd quarter. Raymond James & Associates now owns 1,024,304 shares of the company’s stock valued at $927,384,000 after buying an additional 88,549 shares in the last quarter. MBL Wealth LLC lifted its position in shares of Eli Lilly and Company by 2.4% in the second quarter. MBL Wealth LLC now owns 1,389 shares of the company’s stock valued at $1,258,000 after acquiring an additional 33 shares in the last quarter. ARS Wealth Advisors Group LLC lifted its position in shares of Eli Lilly and Company by 2.2% in the second quarter. ARS Wealth Advisors Group LLC now owns 2,066 shares of the company’s stock valued at $1,870,000 after acquiring an additional 44 shares in the last quarter. OFI Invest Asset Management boosted its stake in shares of Eli Lilly and Company by 25.4% in the second quarter. OFI Invest Asset Management now owns 112,405 shares of the company’s stock worth $94,956,000 after acquiring an additional 22,771 shares during the last quarter. Finally, Oakworth Capital Inc. increased its position in shares of Eli Lilly and Company by 11.1% during the second quarter. Oakworth Capital Inc. now owns 3,805 shares of the company’s stock worth $3,445,000 after purchasing an additional 381 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.
Insider Activity
In related news, major shareholder Lilly Endowment Inc sold 2,052 shares of the company’s stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $809.00, for a total transaction of $1,660,068.00. Following the sale, the insider now directly owns 98,554,195 shares of the company’s stock, valued at approximately $79,730,343,755. The sale was disclosed in a legal filing with the SEC, which is available through this link. In related news, major shareholder Lilly Endowment Inc sold 2,052 shares of the business’s stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $809.00, for a total transaction of $1,660,068.00. Following the completion of the transaction, the insider now directly owns 98,554,195 shares of the company’s stock, valued at approximately $79,730,343,755. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Donald A. Zakrowski sold 750 shares of the stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $819.47, for a total value of $614,602.50. Following the completion of the sale, the chief accounting officer now directly owns 7,130 shares in the company, valued at approximately $5,842,821.10. The disclosure for this sale can be found here. Over the last quarter, insiders sold 1,214,704 shares of company stock valued at $1,066,841,316. 0.13% of the stock is currently owned by company insiders.
Eli Lilly and Company Trading Down 1.0 %
Eli Lilly and Company Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th will be given a dividend of $1.30 per share. The ex-dividend date is Thursday, August 15th. This represents a $5.20 annualized dividend and a dividend yield of 0.56%. Eli Lilly and Company’s dividend payout ratio is presently 76.58%.
Analyst Upgrades and Downgrades
LLY has been the topic of a number of research reports. Jefferies Financial Group raised their price objective on Eli Lilly and Company from $994.00 to $1,015.00 and gave the company a “buy” rating in a report on Monday, June 24th. Berenberg Bank boosted their price target on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a research report on Wednesday. Bank of America upped their price objective on shares of Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Deutsche Bank Aktiengesellschaft raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating and raised their target price for the stock from $725.00 to $1,025.00 in a research note on Monday, August 12th. Finally, Guggenheim upped their price target on Eli Lilly and Company from $884.00 to $1,030.00 and gave the company a “buy” rating in a research report on Friday. Two equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus target price of $956.88.
Check Out Our Latest Stock Analysis on Eli Lilly and Company
Eli Lilly and Company Company Profile
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Further Reading
- Five stocks we like better than Eli Lilly and Company
- The Most Important Warren Buffett Stock for Investors: His Own
- This Small Cap Wealth Management Stock Could Provide Big Returns
- How to Start Investing in Real Estate
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- When to Sell a Stock for Profit or Loss
- MarketBeat Week in Review – 8/12 – 8/16
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.